Hikma has slashed its annual forecast for its US generics business, wiping around $150m off its expected sales for this year following news of a delay to the launch of an authorized generic version of Xyrem (sodium oxybate) that the company had been expecting to introduce midway through 2022.
Noting that originator Jazz had provided an “update to its expectations for the launch timing of an authorized generic of...




